The 74-page slideshow, which Smith said was "roughly" the same as the one shared with the company, called for improvements to Pfizer's drug research and development, spending on acquisitions ...

MCL can be hard to treat because it is aggressive and usually not curable. Jaypirca offers a new option for people with MCL. With targeted action on cancer cells, Jaypirca helps control the ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

When a novel coronavirus struck in early 2020, Pfizer’sPFE-0.74%decrease; red down pointing triangle chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the ...

NEW YORK (Reuters) - Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to ...

INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine ...

Are you a print subscriber? Activate your account. By Tim Nudd - 1 hour 14 min ago By Adrianne Pasquarelli - 5 hours 42 min ago By Erika Wheless - 5 hours 42 min ago By Brian Bonilla - 5 hours 42 ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over ...

NEW YORK (Reuters) - Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to ...